Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye
Launched by HEIDELBERG UNIVERSITY · Apr 23, 2015
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Keratoconus patients after unilateral crosslinking treatment
- Exclusion Criteria:
- • Morphological changes of the cornea caused be ocular infection or trauma (e.g. corneal scarring)
- • Other pre-existing corneal surgery (e.g. corneal transplantation, implantation of intrastromal corneal ring segments)
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Wuerttemberg, Germany
Patients applied
Trial Officials
Mike P Holzer, MD, FEBO
Principal Investigator
Department of ophthalmology, University of Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials